Femasys Stock (NASDAQ:FEMY)

Revenue Ownership Financials Chart

Previous Close

$0.95

52W Range

$0.73 - $2.40

50D Avg

$1.16

200D Avg

$1.26

Market Cap

$21.33M

Avg Vol (3M)

$160.33K

Beta

-2.83

Div Yield

-

FEMY Company Profile

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

32

IPO Date

Jun 18, 2021

Website

FEMY Performance

FEMY Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$1.45M	$1.21M	$1.18M
Operating Income	$-14.51M	$-11.60M	$-8.34M
Net Income	$-14.25M	$-11.39M	$-7.54M
EBITDA	$-13.92M	$-10.81M	$-6.92M
Basic EPS	$-0.93	$-1.26	$-1.12
Diluted EPS	$-0.93	$-1.26	$-1.12

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
NEPH	Nephros, Inc.
KRMD	KORU Medical Systems, Inc.
POCI	Precision Optics Corporation, Inc.
PDEX	Pro-Dex, Inc.
UTMD	Utah Medical Products, Inc.